DENTSPLY SIRONA tops Q2 earnings estimates with margin gains, but revenue declines and U.S. weakness persists.
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply International (XRAY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.49 per share a year ago.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Dentsply International (XRAY) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
XRAY's Imaging strength and SureSmile growth might have lifted Q2 performance, but Byte's drag and macro pressures likely clouded the top-line momentum.
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors interested in Medical - Dental Supplies stocks are likely familiar with Dentsply International (XRAY) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
XRAY gains traction with digital implants, R&D strength, and Q1 margin growth despite softness in Europe.